Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Ana Parra, Claudia Hernández & Laura Prieto-Pinto. (2023) Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-10.
Read now
Read now
Bruce C. Roberts, Christopher Rini, Rick Klug, Douglas B. Sherman, Didier Morel & Ronald J. Pettis. (2022) Novel cannula design improves large volume auto-injection rates for high viscosity solutions. Drug Delivery 29:1, pages 43-51.
Read now
Read now
Advait V Badkar, Rajesh B Gandhi, Shawn P Davis & Michael J LaBarre. (2021) Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements. Drug Design, Development and Therapy 15, pages 159-170.
Read now
Read now
Robert S Epstein. (2021) Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs. ClinicoEconomics and Outcomes Research 13, pages 801-807.
Read now
Read now
Christian Klein, Candice Jamois & Tina Nielsen. (2021) Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opinion on Biological Therapy 21:2, pages 161-181.
Read now
Read now
Olga Delgado Sánchez, Antonio Gutiérrez, Fernando do Pazo, Jordi Ginés, Clara Martorell, Bàrbara Boyeras, Leyre Bento, Marta Garcia-Recio & Antonia Sampol. (2019) Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients. ClinicoEconomics and Outcomes Research 11, pages 695-701.
Read now
Read now
Kenneth W. Locke, Daniel C. Maneval & Michael J. LaBarre. (2019) ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20. Drug Delivery 26:1, pages 98-106.
Read now
Read now
Clemente Ponzetti, Monica Canciani, Massimo Farina, Sara Era & Stefan Walzer. (2016) Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. ClinicoEconomics and Outcomes Research 8, pages 227-233.
Read now
Read now
Jing-fen Jin, Ling-ling Zhu, Meng Chen, Hui-min Xu, Hua-fen Wang, Xiu-qin Feng, Xiu-ping Zhu & Quan Zhou. (2015) The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Preference and Adherence 9, pages 923-942.
Read now
Read now
Richard T North, Vernon J Harvey, Levonne C Cox & Stuart N Ryan. (2015) Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study. ClinicoEconomics and Outcomes Research 7, pages 423-430.
Read now
Read now
Philippe Solal-Celigny. (2015) Rituximab by subcutaneous route. Expert Review of Hematology 8:2, pages 147-153.
Read now
Read now
Articles from other publishers (38)
Lorenzo Pradelli, Massimo Massaia, Elisabetta Todisco, Filippo Gherlinzoni, Anna Furlan, Maria La Targia, Elisabetta Grande, Ignazio Ezio Tripoli, Francesca Occhipinti, Francesco Comello, Fabrizio Iannello & Stefania Bellucci. (2023) Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers. Cancer Medicine.
Crossref
Crossref
Amir Erfani, Paul Reichert, Chakravarthy N. Narasimhan & Patrick S. Doyle. (2023) Injectable hydrogel particles for amorphous solid formulation of biologics. iScience 26:8, pages 107452.
Crossref
Crossref
Amir Erfani, Jeremy M. Schieferstein, Paul Reichert, Chakravarthy N. Narasimhan, Cinthia Pastuskovas, Vaishali Parab, Denarra Simmons, Xiaoyu Yang, Apoorv Shanker, Paula Hammond & Patrick S. Doyle. (2023) Crystalline Antibody‐Laden Alginate Particles: A Platform for Enabling High Concentration Subcutaneous Delivery of Antibodies. Advanced Healthcare Materials 12:15.
Crossref
Crossref
Ana Muntañola, José María Arguiñano‐Pérez, Julio Dávila, Sonia González de Villambrosia, Cecilia Carpio, Ana Jiménez‐Ubieto & Antonio Salar. (2022) Safety and tolerability of a 90‐minute rapid infusion of Sandoz biosimilar rituximab in B‐cell lymphoproliferative disorders in a real‐world setting. Clinical and Translational Science 16:2, pages 305-312.
Crossref
Crossref
Conor McCloskey, María Toboso Ortega, Sunita Nair, Maria João Garcia & Federico Manevy. (2022) A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting. PharmacoEconomics - Open 7:1, pages 3-36.
Crossref
Crossref
Michael J. Harvey, Yi Zhong, Eric Morris, Jacob N. Beverage, Robert S. Epstein & Anita J. Chawla. (2022) Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma. PLOS ONE 17:1, pages e0261336.
Crossref
Crossref
Wendy D. Woodley, Didier R. Morel, Diane E. Sutter, Ronald J. Pettis & Natasha G. Bolick. (2021) Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults. Clinical and Translational Science 15:1, pages 92-104.
Crossref
Crossref
Beate Bittner & Johannes Schmidt. 2022. Formulation and Device Lifecycle Management of Biotherapeutics. Formulation and Device Lifecycle Management of Biotherapeutics
175
200
.
Beate Bittner & Johannes Schmidt. 2022. Formulation and Device Lifecycle Management of Biotherapeutics. Formulation and Device Lifecycle Management of Biotherapeutics
47
83
.
María Reyes Abad-Sazatornil, Ainhoa Arenaza, Juan Bayo, Jesus García Mata, José María Guinea De Castro, Josefa León, Javier Letellez, Virginia Reguero, Carmen Martínez Chamorro & Antonio Salar. (2021) Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study. BMC Health Services Research 21:1.
Crossref
Crossref
Catherine Diefenbach, Brad S Kahl, Andrew McMillan, Javier Briones, Lalita Banerjee, Raul Cordoba, Fiona Miall, John M Burke, Jamie Hirata, Yanwen Jiang, Joseph N Paulson, Yi Meng Chang, Lisa Musick & Pau Abrisqueta. (2021) Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. The Lancet Haematology 8:12, pages e891-e901.
Crossref
Crossref
Simon Rule, Wolney Gois Barreto, Javier Briones, Angelo M. Carella, Olivier Casasnovas, Chris Pocock, Clemens-Martin Wendtner, Francesco Zaja, Susan Robson, Lachlan MacGregor, Roger R. Tschopp, Sonja Nick & Martin Dreyling. (2021) Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute study. Haematologica 107:2, pages 500-509.
Crossref
Crossref
Wendy D. Woodley, Wen Yue, Didier R. Morel, Audrey Lainesse, Ronald J. Pettis & Natasha G. Bolick. (2021) Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects. Clinical and Translational Science 14:3, pages 859-869.
Crossref
Crossref
Andrea Allmendinger. (2021) Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products. Pharmaceutical Research 38:5, pages 739-757.
Crossref
Crossref
Theerajet Guayboon, Yingyong Chinthammitr, Sanya Sukpanichnant, Navin Horthongkham & Nasikarn Angkasekwinai. (2021) Human herpesvirus 8-associated multicentric Castleman disease in a patient with advanced HIV infection. Medicine 100:49, pages e28077.
Crossref
Crossref
Minyoung Jang, Steven Simoens & Taeksang Kwon. (2020) Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets. BioDrugs 35:1, pages 89-101.
Crossref
Crossref
Jesse H. Erasmus, Jacob Archer, Jasmine Fuerte-Stone, Amit P. Khandhar, Emily Voigt, Brian Granger, Robin G. Bombardi, Jennifer Govero, Qing Tan, Lorellin A. Durnell, Rhea N. Coler, Michael S. Diamond, James E. CroweJr.Jr., Steven G. Reed, Larissa B. Thackray, Robert H. Carnahan & Neal Van Hoeven. (2020) Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection. Molecular Therapy - Methods & Clinical Development 18, pages 402-414.
Crossref
Crossref
David S. Collins, Manuel Sánchez-Félix, Advait V. Badkar & Randall Mrsny. (2020) Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. Journal of Controlled Release 321, pages 475-482.
Crossref
Crossref
Kenneth C Anderson, Ola Landgren, Rebecca C Arend, Jeffrey Chou & Ira A Jacobs. (2019) Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncology 15:28, pages 3267-3281.
Crossref
Crossref
Jillian Pintye, Alison L. Drake, Emily Begnel, John Kinuthia, Felix Abuna, Harison Lagat, Julia Dettinger, Anjuli D. Wagner, Harsha Thirumurthy, Kenneth Mugwanya, Jared M. Baeten & Grace John-Stewart. (2019) Acceptability and outcomes of distributing HIV self-tests for male partner testing in Kenyan maternal and child health and family planning clinics. AIDS 33:8, pages 1369-1378.
Crossref
Crossref
Changrim Lee, Hao Guo, Wannita Klinngam, Srikanth R. Janga, Frances Yarber, Santosh Peddi, Maria C. Edman, Nishant Tiwari, Siyu Liu, Stan G. Louie, Sarah F. Hamm-Alvarez & J. Andrew MacKay. (2019) Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease. Molecular Pharmaceutics 16:7, pages 3024-3039.
Crossref
Crossref
Gary L. O'Brien, Cian O'Mahony, Katie Cooke, Ada Kinneally, Sarah-Jo Sinnott, Valerie Walshe, Mark Mulcahy & Stephen Byrne. (2019) Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland. Clinical Breast Cancer 19:3, pages e440-e451.
Crossref
Crossref
Jillian Pintye, John Kinuthia, D. Allen Roberts, Anjuli D. Wagner, Kenneth Mugwanya, Felix Abuna, Harison Lagat, George Owiti, Carol E. Levin, Ruanne V. Barnabas, Jared M. Baeten & Grace John-Stewart. (2018) Brief Report: Integration of PrEP Services Into Routine Antenatal and Postnatal Care: Experiences From an Implementation Program in Western Kenya. JAIDS Journal of Acquired Immune Deficiency Syndromes 79:5, pages 590-595.
Crossref
Crossref
Ciara L. Freeman & Laurie Sehn. (2018) Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?. Current Oncology Reports 20:12.
Crossref
Crossref
Beate Bittner, Wolfgang Richter & Johannes Schmidt. (2018) Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs 32:5, pages 425-440.
Crossref
Crossref
Margreet G. Franken, Tim A. Kanters, Jules L. Coenen, Paul de Jong, Harry R. Koene, Pieternella J. Lugtenburg, Agnes Jager & Carin A. Uyl-de Groot. (2018) Potential cost savings owing to the route of administration of oncology drugs. Anti-Cancer Drugs 29:8, pages 791-801.
Crossref
Crossref
Samuel Luke Hill & Andrew Davies. (2018) Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Future Oncology 14:17, pages 1691-1699.
Crossref
Crossref
Samuel H. Burrows, Oluwatosin Akinbobuyi, Simon Rule & Nicola Crosbie. (2018) Subcutaneous rituximab can be safely administered without pre-medication. British Journal of Haematology 181:6, pages 836-837.
Crossref
Crossref
Jens Olsen, Kenneth Forsstrøm Jensen, Daniel Sloth Olesen & Ann Knoop. (2018) Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer. Journal of Comparative Effectiveness Research 7:5, pages 411-419.
Crossref
Crossref
Debra Pollard & Steve Chaplin. (2018) Subcutaneous injection: learning from experience in other specialties. The Journal of Haemophilia Practice 5:1, pages 35-41.
Crossref
Crossref
Emilie Fargier, Florence Ranchon, Laure Huot, Pascale Guerre, Violaine Safar, Arthur Dony, Nathalie Hequet, Emmanuel Bachy, Stéphane Savouroux, Clémentine Fronteau, Patrick Tomaré, Jean-François Tournamille, Vérane Schwiertz, Nicolas Vantard, Steven Le Gouill, Emmanuel Gyan, Gilles Salles & Catherine Rioufol. (2017) SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Annals of Hematology 97:1, pages 123-131.
Crossref
Crossref
Alberto Farolfi, Paolo Silimbani, Davide Gallegati, Elisabetta Petracci, Alessio Schirone, Mattia Altini & Carla Masini. (2017) Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients. Oncotarget 8:46, pages 81343-81349.
Crossref
Crossref
Andrew Davies, Claude Berge, Axel Boehnke, Anjum Dadabhoy, Pieternella Lugtenburg, Simon Rule, Mathias Rummel, Christine McIntyre, Rodney Smith & Xavier Badoux. (2017) Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Advances in Therapy 34:10, pages 2210-2231.
Crossref
Crossref
Lu Zhang, Michele Ghielmini, Bruce D. Cheson & Chaitra Ujjani. (2017) Pros and cons of rituximab maintenance in follicular lymphoma. Cancer Treatment Reviews 58, pages 34-40.
Crossref
Crossref
Jovan Mihajlović, Pieter Bax, Erwin van Breugel, Hedwig M. Blommestein, Mels Hoogendoorn, Wobbe Hospes & Maarten J. Postma. (2017) Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. Clinical Therapeutics 39:6, pages 1221-1232.e4.
Crossref
Crossref
Erwin De Cock, Persefoni Kritikou, Mariana Sandoval, Sunning Tao, Christof Wiesner, Angelo Michele Carella, Charles Ngoh & Tim Waterboer. (2016) Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries. PLOS ONE 11:6, pages e0157957.
Crossref
Crossref
Sarit Assouline, Valeria Buccheri, Alain Delmer, Gianluca Gaidano, Marek Trneny, Natalia Berthillon, Michael Brewster, Olivier Catalani, Sai Li, Christine McIntyre, Pakeeza Sayyed & Xavier Badoux. (2016) Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. The Lancet Haematology 3:3, pages e128-e138.
Crossref
Crossref
Julia Carlson, Keith Cox, Kylie Bedwell & Mathew Ku. (2015) Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective. International Journal of Nursing Practice 21, pages 1-13.
Crossref
Crossref